August 16, 2006 -- Penwest Pharma will initiate the dispute resolution procedures of its agreement with Endo Pharma over the launch costs of opioid drug Opana ER; Cytogen will begin marketing Soltamox, an oral formulation of tamoxifen; the BioDelivery Sciences BEMA pain medication passed its Phase I tests; CV Therapeutics sold 9 million shares at $9.50 each; TolerRx brought in $35.6 million to fund a Phase III trial of its type I diabetes drug; Sirion Therapeutics will buy out fellow ophthalmology company Sytera; BioMS Medical said its multiple sclerosis drug passed the fifth review of the Data Safety Board; and Cempra Pharma closed a $14 million A round of financing. The Centient Biotech 200™ moved up a substantial 58 points to 3691.14, a gain of 1.60%. More details...
